Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Statement of Comprehensive Income 

Bristol-Myers Squibb Co., consolidated statement of comprehensive income

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net earnings (loss) 8,040 6,345 7,014 (8,995) 3,460
Derivatives qualifying as cash flow hedges (230) 54 415 (256) (32)
Pension and postretirement benefits (115) 145 206 (75) 1,203
Marketable debt securities 2 (2) (9) 5 36
Foreign currency translation 78 (210) (41) 7 35
Other comprehensive income (loss) (265) (13) 571 (319) 1,242
Comprehensive income (loss) 7,775 6,332 7,585 (9,314) 4,702
Comprehensive income attributable to noncontrolling interest (15) (18) (20) (20) (21)
Comprehensive income (loss) attributable to BMS 7,760 6,314 7,565 (9,334) 4,681

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Comprehensive income item Description The company
Net earnings (loss) attributable to BMS The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Bristol-Myers Squibb Co. net earnings (loss) attributable to BMS decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Comprehensive income (loss) attributable to BMS Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Exclude changes in equity resulting from investments by owners and distributions to owners. Bristol-Myers Squibb Co. comprehensive income (loss) attributable to BMS decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.